Tags

Type your tag names separated by a space and hit enter

Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Prescrire Int. 2011 Apr; 20(115):95.PI

Abstract

The cholinesterase inhibitors donepezil, rivastigmine and galantamine have a modest and transient benefit in Alzheimer's disease. Their known adverse effects include bradycardia. A Canadian case-control study conducted between 2003 and 2008 showed a statistically significant increase in the risk of hospitalisation for bradycardia among patients who had been taking a cholinesterase inhibitor for less than 3 months, compared with patients who had stopped taking a cholinesterase inhibitor more than 6 months previously. After hospital discharge, more than half of these patients were again prescribed a cholinesterase inhibitor, and 4% of them were re-admitted for bradycardia. In practice, when an adverse effect has been identified and treated, this information must be shared and taken into account by all those involved in the patient's subsequent management.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21648211

Citation

"Bradycardia Due to Cholinesterase Inhibitors: Identify Adverse Effects and Take Them Into Account." Prescrire International, vol. 20, no. 115, 2011, p. 95.
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. Prescrire Int. 2011;20(115):95.
(2011). Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. Prescrire International, 20(115), 95.
Bradycardia Due to Cholinesterase Inhibitors: Identify Adverse Effects and Take Them Into Account. Prescrire Int. 2011;20(115):95. PubMed PMID: 21648211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. PY - 2011/6/9/entrez PY - 2011/6/9/pubmed PY - 2011/6/29/medline SP - 95 EP - 95 JF - Prescrire international JO - Prescrire Int VL - 20 IS - 115 N2 - The cholinesterase inhibitors donepezil, rivastigmine and galantamine have a modest and transient benefit in Alzheimer's disease. Their known adverse effects include bradycardia. A Canadian case-control study conducted between 2003 and 2008 showed a statistically significant increase in the risk of hospitalisation for bradycardia among patients who had been taking a cholinesterase inhibitor for less than 3 months, compared with patients who had stopped taking a cholinesterase inhibitor more than 6 months previously. After hospital discharge, more than half of these patients were again prescribed a cholinesterase inhibitor, and 4% of them were re-admitted for bradycardia. In practice, when an adverse effect has been identified and treated, this information must be shared and taken into account by all those involved in the patient's subsequent management. SN - 1167-7422 UR - https://www.unboundmedicine.com/medline/citation/21648211/Bradycardia_due_to_cholinesterase_inhibitors:_identify_adverse_effects_and_take_them_into_account_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.